Oncologist

• 

  Publication Venue For

  • Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles..  28:208-213. 2023
  • A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?.  28:105-115. 2023
  • The Value of Phenotypic Precision Medicine in Prostate Cancer..  28:93-104. 2023
  • A Qualitative Exploration of Barriers to Treatment Among HPV-Positive Women in a Cervical Cancer Screening Study in Western Kenya..  28:e9-e18. 2023
  • Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board..  28:33-39. 2023
  • Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma..  27:809-e765. 2022
  • Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization..  27:711-713. 2022
  • Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma..  27:621-e617. 2022
  • Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance)..  27:e494-e505. 2022
  • First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape..  27:125-134. 2022
  • Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers..  27:e37-e44. 2022
  • First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors..  26:925-e1918. 2021
  • Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)..  26:560-e1103. 2021
  • Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer..  26:465-e917. 2021
  • Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors..  26:e622-e631. 2021
  • An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC)..  26:e508-e511. 2021
  • Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation..  26:224-230. 2021
  • Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729)..  26:e435-e444. 2021
  • A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study..  25:963-973. 2020
  • A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study..  25:e1655-e1662. 2020
  • Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019..  25:819-821. 2020
  • Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs..  25:e405-e411. 2020
  • Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy..  25:33-45. 2020
  • A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN..  24:1510-e1265. 2019
  • Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial..  24:1497-1501. 2019
  • Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer..  24:1453-1461. 2019
  • The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). 2019
  • Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia..  24:1253-1258. 2019
  • Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)..  24:921-932. 2019
  • Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)..  24:e284-e291. 2019
  • Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer..  24:762-771. 2019
  • Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101..  24:617-623. 2019
  • Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine..  24:e103-e105. 2019
  • An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma..  24:202-210. 2019
  • Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia..  24:247-254. 2019
  • Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602)..  23:1016-1023. 2018
  • Development and Validation of a Clinical Score for Cardiovascular Risk Stratification of Long-Term Childhood Cancer Survivors..  23:965-973. 2018
  • Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma..  23:889-e98. 2018
  • A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer..  23:782-790. 2018
  • Costs of Cancer Care Across the Disease Continuum..  23:798-805. 2018
  • Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies..  23:403-409. 2018
  • Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer..  22:642-647. 2017
  • Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer..  22:375-e30. 2017
  • Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials..  22:189-198. 2017
  • A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803..  22:107-114. 2017
  • A Touchy Subject: Can Physicians Improve Value by Discussing Costs and Clinical Benefits With Patients?.  21:1157-1160. 2016
  • Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry..  21:1079-1084. 2016
  • FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies..  21:931-939. 2016
  • A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial..  21:789-794. 2016
  • Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer..  21:676-683. 2016
  • Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies..  20:773-779. 2015
  • Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma..  20:727-728. 2015
  • Regional variation in identified cancer care needs of early-career oncologists in China, India, and Pakistan..  20:532-538. 2015
  • A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer..  20:105-106. 2015
  • Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop..  20:186-195. 2015
  • Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients..  19:999-1005. 2014
  • Self-reported financial burden and satisfaction with care among patients with cancer..  19:414-420. 2014
  • New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing..  19:235-242. 2014
  • Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects..  19:127-134. 2014
  • Comparative effectiveness research in oncology..  18:752-759. 2013
  • Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting..  18:760-767. 2013
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas..  18:271-272. 2013
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies..  18:273-280. 2013
  • Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials..  18:1004-1012. 2013
  • Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review..  18:54-63. 2013
  • The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience..  18:381-390. 2013
  • The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics..  18:221-231. 2013
  • Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis..  18:1321-1329. 2013
  • A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard)..  17:937-946. 2012
  • Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer..  17:1551-1561. 2012
  • Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer..  17:513-524. 2012
  • Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability..  17:9-10. 2012
  • Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer..  17:1496-1503. 2012
  • Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study..  17:1486-1495. 2012
  • A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer..  16:1131-1137. 2011
  • Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy..  16:1714-1720. 2011
  • An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions..  16:1397-1402. 2011
  • Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score..  16:1359-1366. 2011
  • Cardiovascular complications of breast cancer therapy in older adults..  16:1138-1143. 2011
  • DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer..  16:61-70. 2011
  • A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603)..  15:1310-1319. 2010
  • A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium..  15:810-818. 2010
  • A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer..  15:845-851. 2010
  • Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study..  15:636-647. 2010
  • Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study..  15:1329-1334. 2010
  • Economic burden for informal caregivers of lung and colorectal cancer patients..  15:883-893. 2010
  • Integrative and behavioral approaches to the treatment of cancer-related neuropathic pain..  15 Suppl 2:19-23. 2010
  • Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer..  15:577-583. 2010
  • Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature..  14:816-827. 2009
  • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer..  14:22-28. 2009
  • Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer..  13:1021-1029. 2008
  • Strategies of Antiretroviral Therapy in Adults..  3:111-118. 1998
  • Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. 2018
  • In Reply..  25:e744-e745. 2020
  • Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy. 2016
  • Patient experience and attitudes toward addressing the cost of breast cancer care. 2014